Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study.
Functional Homotopic Changes in Multiple Sclerosis with Resting-State Functional MR Imaging.
Poppers toxic maculopathy misdiagnosed as atypical optic neuritis.
Helicobacter pylori serology in autoimmune diseases - fact or fiction?
Pediatric Multiple Sclerosis with Primary Progressive Course-Report of a Retrospective Cohort Study in Iran.
Multiple sclerosis: Monotherapy rules.
Childhood transverse myelitis and its mimics.
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720).
A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease.
Relapsing and progressive forms of multiple sclerosis: insights from pathology.
Role of iNOS-NO-cGMP signaling in modulation of inflammatory and myelination processes.
Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.
Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis.
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool.
Targeting of aquaporin 4 into lipid rafts and its biological significance.
Update on Disease-Modifying Treatments for Multiple Sclerosis.
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
Fully automatic detection of deep white matter T1 hypointense lesions in multiple sclerosis.
Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response.
FRACTALKINE GENE RECEPTOR POLYMORPHISM IN PATIENTS WITH MULTIPLE SCLEROSIS.
Therapeutic plasma exchange in the neurologic intensive care setting recommendation for clinical practice.
Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates.
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
339
340
341
342
343
344
345
346
347
…
next ›
last »